⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 7, 2024The Journal of Infectious DiseasesOpen Access

Cost-effectiveness of 4CMenB Vaccination Against Gonorrhea: Importance of Dosing Schedule, Vaccine Sentiment, Targeting Strategy, and Duration of Protection

Dariya Nikitin Lilith K. Whittles Jeffrey W. Eaton Peter J White

View Full Paper

Ask AI

Bookmark

Share

Abstract

Observational evidence suggests the 4CMenB meningococcal vaccine may partially protect against gonorrhea, with one dose being two-thirds as protective as two. We examined the cost-effectiveness of vaccinating men-who-have-sex-with-men (MSM) in England, with one- or two-dose primary vaccination.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nikitin et al. (2024) studied this question.

synapsesocial.com/papers/68e7542bb6db6435876cbf8c https://doi.org/10.1093/infdis/jiae123

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Randomised trials of meningococcal B (4CMenB) vaccination for the prevention of gonorrhoeaMeta-Analysis · 2026
2Evaluating cross-protection: Meningococcal vaccines show effectiveness in gonorrhoea prevention – A systematic review and meta-analysisMeta-Analysis · 2025 · 4 citations
3Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO)RCT · 2026 · 16 citations
4Effectiveness of the four-component protein-based meningococcal vaccine against Neisseria gonorrhoeae infections: Mounting evidence and public health implications for Canada2025 · 3 citations
5The United Kingdom meningococcal vaccine (4CMenB) programme against gonorrhoea: a review of the evidence and knowledge gaps2025 · 16 citations